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De novo donor-specific antibody (dnDSA) is associ-
ated with antibody-mediated rejection (AMR) and
allograft loss, yet the allograft histology associated
with dnDSA remains unclear. The aim of this study
was to examine the allograft histology associated
with dnDSA in patients with serial surveillance biop-
sies. We retrospectively studied adult conventional
solitary kidney transplant recipients from October
2007 to May 2014. The definition of dnDSA was new
donor-specific antibody (DSA) with mean fluores-
cence intensity (MFI) >1000. The incidence of dnDSA
was 7.0% (54 of 771) over mean follow-up of
4.2  1.9 years. Patients with dnDSA had reduced
death-censored allograft survival (87.0% vs. 97.0% no
dnDSA, p < 0.01). Moreover, 94% of patients received
a biopsy after dnDSA (mean of three biopsies per
patient). AMR was present in 25.0% and 52.9% of
patients at dnDSA detection and at 1 year, respec-
tively. Patients with both class I and II dnDSA had the
highest rate of allograft loss. The higher the sum MFI
at dnDSA detection, the higher the incidence of AMR.
In conclusion, patients with dnDSA without AMR at
time of detection may benefit from a follow-up biopsy
within 1 year because AMR can be missed initially. In
addition, the dnDSA class and sum MFI at baseline
appear to be prognostic. The higher the sum MFI of
dnDSA at baseline, the higher the incidence of AMR.
Abbreviations: AMR, antibody-mediated rejection;
BSA, body surface area; CI, confidence interval; cPRA,
calculated panel reactive antibody; dnDSA, de novo
donor-specific antibody; DSA, donor-specific antibody;
eGFR, estimated GFR; ESRD, end-stage renal disease;
IQR, interquartile range; IVIG, intravenous
immunoglobulin; MFI, mean fluorescence intensity;
NA, not assessed; OR, odds ratio; SAB, single antigen
bead; SD, standard deviation
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Introduction
De novo donor-specific antibody (dnDSA) is a major risk
factor for chronic antibody-mediated rejection (AMR) and
allograft loss (1–5). The reported incidence of dnDSA var-
ies from 6.2% to 27.8% depending on the cohort studied
(2–4,6–9), and up to 24% of allografts fail within 3 years of
dnDSA detection (3). Medication nonadherence and previ-
ous acute cellular rejection in the setting of class II HLA
mismatch are the main risk factors for dnDSA develop-
ment (2,3,6), yet a subset of transplant recipients develop
early dnDSA for reasons that are unclear. Regardless, no
available therapy has been proven effective, emphasizing
the need for prevention and therapeutic clinical trials.
The problem is that designing a clinical trial to prevent or
treat patients with dnDSA is difficult. The number of
patients who develop dnDSA is relatively small. Not all
patients with dnDSA develop AMR or graft loss, and
many patients have stable allograft function for years (6).
Including these patients in a clinical trial is not ideal
because they would receive unnecessary treatment,
which would dilute any treatment effect, thus necessitat-
ing a larger trial. Enriching a study population with
patients who are the most likely to progress to a mean-
ingful clinical end point is a critical component in the
design of an effective clinical trial.
Our goal was to examine serial allograft biopsies in
patients with dnDSA to identify a subgroup of patients
most likely to progress to allograft failure. We also aimed
to identify potentially modifiable risk factors for dnDSA
outside of medication nonadherence, acute cellular rejec-
tion, and HLA mismatch. We studied a predominantly
white living donor kidney transplant population that
underwent surveillance donor-specific antibody (DSA)
testing and allograft biopsy.
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Materials and Methods
This study was approved by the Mayo Clinic institutional review board.
We performed a retrospective cohort study of the risk factors and out-
comes of our adult solitary conventional kidney transplant recipients who
were transplanted between October 2007 and May 2014. We studied
only the initial transplant from patients who were retransplanted at our
center during the studied time period (n = 5), and we excluded patients if
no baseline single antigen bead (SAB) results were available (n = 8), if
DSA was not tested after transplant (n = 25), or if the patient had a posi-
tive crossmatch and/or DSA was detected with mean fluorescence inten-
sity (MFI) >1000 at the time of transplant (n = 158). Data was collected
by chart review. Patients were censored at last follow-up.
Assessment of dnDSA
A SAB solid-phase assay (LABScreen; One Lambda, Canoga Park, CA)
was used to identify alloantibody specificities at baseline and after trans-
plant. The definition of dnDSA was any DSA identified after transplant
that reached MFI >1000 that was not detected at any time prior to trans-
plant (each patient had at least one SAB test prior to transplant). Our cen-
ter protocol is to obtain SABs at least yearly when patients are on the
kidney transplant waiting list, immediately before transplant, 4 mo after
transplant, and yearly after transplant thereafter. SABs are also routinely
performed at the time of allograft dysfunction or acute cellular rejection.
Assessment of medication adherence
This information was obtained from the clinical record. We defined medi-
cal nonadherence as documented missing labs, unexplained low immuno-
suppressive drug levels, missed appointments, medications not refilled,
or patients who were admittedly nonadherent.
Biopsy assessment
Surveillance biopsies were done at 4, 12, 24, and 60 mo after transplant
as standard of care. Biopsies were also performed for allograft dysfunc-
tion, proteinuria, or based on provider discretion (i.e. known dnDSA). Kid-
ney biopsy tissue was processed for light microscopy and C4d by
immunofluorescence (Bio-Rad Antibodies [formerly AbD Serotec],
Raleigh, NC), if indicated.
Light microscopy features of biopsies were scored by slightly modified
Banff criteria (10–12). Specifically; acute active AMR was diagnosed in
patients with dnDSA if three features were present according to Banff
2013 guidelines: (i) histologic evidence of acute tissue injury including
glomerulitis (g >0) and/or peritubular capillaritis (ptc >0), intimal or trans-
mural arteritis (v >0), thrombotic microangiopathy, or acute tubular injury,
in the absence of any other apparent cause; (ii) evidence of current
or recent antibody interaction with vascular endothelium including
C4d ≥2 with immunofluorescence on frozen section and/or g + ptc ≥2;
and (iii) serologic evidence of DSAs.
The presence of transplant glomerulopathy (cg >0) signified chronic AMR.
In this study, patients with acute, active AMR could have cg >0, which is
a modification from the Banff 2013 guidelines; therefore, some patients
met criteria for acute, active AMR and chronic AMR simultaneously. Elec-
tron microscopy was not routinely done in all cases, and it was not used
to determine the presence of chronic AMR.
Immunosuppression and treatment protocols
Patients received anti–thymocyte globulin (ATG; Thymoglobulin; Sang-
stadt, Menlo Park, CA), 1.5 mg/kg per day for four doses; anti-CD25
receptor antibodies (Simulect, Novartis Pharmaceuticals, East Hanover,
NJ); or alemtuzumab (Campath; Genzyme, Cambridge, MA) as induction
per center protocol. Currently, alemtuzumab is the standard induction
agent if the patient age is <65 years, the B cell flow cytometric cross-
match is negative, and no DSA is detected with MFI >2000; anti-CD25
receptor antibodies are given if the patient is ≥65 years with a negative
crossmatch; and ATG is given to all other patients. Prior to 2011, alem-
tuzumab was not part of routine protocol. At that time, ATG was given to
all patients unless they were aged ≥65 years and had a negative B cell
flow cytometric crossmatch, in which case they received anti-CD25
receptor antibodies.
Standard maintenance immunosuppression consisted of prednisone,
tacrolimus, and mycophenolate mofetil in patients who receive induction
with ATG and anti-CD25 antibodies. Patients were on a steroid-free
immunosuppression protocol if they received alemtuzumab induction
(tacrolimus and mycophenolate mofetil only).
Because no therapy has been proven effective for the sustained reduc-
tion in DSA, no specific therapy for dnDSA was given outside of routine
treatment for acute cellular rejection, mixed acute cellular rejection and
AMR, or low immunosuppressive levels. Specifically, 75.9% (42 of 54)
patients received no new therapy during follow-up; 11.1% (6 of 54)
received thymoglobulin, intravenous immunoglobulin (IVIG), and plasma-
pheresis for mixed acute cellular rejection and AMR; 9.3% (5 of 54)
received corticosteroids for acute cellular rejection alone; and 1.9% (1 of
54) received IVIG therapy alone.
Laboratory monitoring
All patients had their serum creatinine and estimated GFR (eGFR)
assessed at least every 3 mo. At yearly intervals, patients had more thor-
ough assessment of their renal function that included iothalamate clear-
ance testing and 24-h urine protein testing.
Statistical analysis
Statistical analysis was performed on JMP v10 (SAS Institute, Cary, NC).
For numerical data, groups were compared with the t-test or the Wil-
coxon rank sum test, as indicated. Counts and percentages were com-
pared using the Fisher exact test. Odds ratios (ORs) were used and
described by their point estimate and corresponding 95% confidence
intervals (CIs). Logistic regression was used for multivariate analysis to
determine the risk factors for dnDSA. Time-to-event data were summa-
rized for each group using Kaplan–Meier estimates. Cox regression with
a time-dependent variable (dnDSA) was used to test between groups
(Wald test at the 0.05 level). Testing was two-sided at the 0.05 level. The
paired t-test was used to compare paired continuous data, and the
McNemar test was used to compare paired proportions.
Results
Demographics
Figure 1 shows a flow chart of the patients in the study.
Baseline characteristics are shown in Table 1. Overall
mean follow-up was 4.2 + 1.9 years and was similar
among those developing dnDSA and those in whom
dnDSA was never detected. The incidence of dnDSA
was 7.0% during this time frame. In our cohort, the
transplant recipients were predominantly white, and
82.3% (637 of 771) received their transplant from a living
donor. There was no difference in sex, race, donor type,
cause of end-stage renal disease, calculated panel reac-
tive antibody, prior organ transplant, or prior polyomavirus
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among patients who did or did not develop dnDSA.
Patients who developed dnDSA were younger (mean
age 48.3  15.6 vs. 53.0  13.8 years, p = 0.04) and
had more HLA mismatches (mean 4.2  1.5 vs.
3.6  1.9, p < 0.01). The majority of patients received
thymoglobulin for induction immunosuppression, but
there was a higher proportion of patients who received
alemtuzumab in the dnDSA cohort than the non-dnDSA
cohort (31.5% [17 of 54] vs. 18.2% [130 of 717],
p = 0.03). There were also more patients in the dnDSA
group who had a prior acute cellular rejection episode
(35.2% [19 of 54] vs. 15.8% [113 of 717], p < 0.01) or
had a documented history of medication nonadherence.
Risk factors for dnDSA
Patients aged >60 years were less likely to develop
dnDSA in our cohort based on univariate analysis (OR 0.5
[95% CI 0.3–1.0], p = 0.04) (Table 2). Risk factors for the
development of dnDSA based on univariate analysis
were alemtuzumab induction (OR 2.1 [95% CI 1.1–3.8],
p = 0.03); HLA mismatches at the A locus (OR 4.5 [95%
CI 1.6–12.5], p < 0.01), DR locus (OR 3.2 [95% CI
1.3–8.1], p = 0.01), and DQ locus (OR 4.6 [95% CI 1.8–
11.7], p < 0.01); prior acute cellular rejection (OR 2.9
[95% CI 1.6–5.2], p < 0.01); and documented medication
nonadherence (OR 7.5 [95% CI 3.9–14.2], p < 0.01).
Independent risk factors for dnDSA determined by multi-
variate models were DQ mismatch (OR 4.8 [95% CI 2.0–
14.3], p < 0.01), prior history of acute cellular rejection
(OR 2.4 [95% CI 1.3–4.5], p < 0.01), and documented
medication nonadherence (OR 7.9 [95% CI 3.9–15.4],
p < 0.01) (Table 2, multivariate model 2).
Characteristics of dnDSA
Overall, 7% of patients developed dnDSA. The mean
time to dnDSA detection after transplant was 1.8 
1.6 years (Figure 2), and 3.2% (25 of 771) of patients
developed dnDSA within 1 year after transplant. Anti–
class I DSA alone was present in 9.3% (5 of 54), anti–
class II DSA alone was present in 70.4% (38 of 54), and
anti–class I and II DSA was present in 20.4% (11 of 54)
of patients (Table 3). In total, 29.6% (16 of 54) had anti–
class I dnDSA and 90.7% (49 of 54) had anti–class II
dnDSA. The dnDSA completely disappeared during
Figure 1: Patients studied. dnDSA, de novo donor-specific antibody; DSA, donor-specific antibody; SAB, single antigen bead.
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follow-up in 16.7% (9 of 54) of patients. The distribution
of dnDSA MFI is shown in Table 3.
Allograft survival
Patient and overall allograft survival were similar among
patients who did or did not develop dnDSA, as shown in
Figure 3; however, patients with dnDSA had reduced
death-censored allograft survival (p = 0.01). Actuarial
death-censored allograft survival was 87.0% in patients
who developed dnDSA and 97.0% in patients who did
not develop dnDSA (p = 0.01). The mean time to
death-censored allograft failure after dnDSA detection
was 1.6  1.7 years.
Progression of clinical and subclinical AMR
In total, 160 biopsies were obtained from 94.4% (51 of
54) of the studied patients at the time of dnDSA detec-
tion or afterward (mean of three biopsies per patient).
Biopsies were obtained at the time of dnDSA detection
in 74.1% (40 of 54) of patients. At 1 year after dnDSA
detection, biopsies were obtained in 68.0% (34 of 50) of
the surviving patients with a functioning allograft.
Table 1: Baseline demographics
Characteristic
All patients
N = 771
dnDSA
n = 54
No dnDSA
n = 717 p-value
Age (years), mean  SD 52.6  13.9 48.3  15.6 53.0  13.8 0.04
18–30 years, n (%) 55 (8.4) 8 (14.8) 57 (8.0)
>30–40 years, n (%) 78 (10.1) 8 (14.8) 70 (9.8)
>40–50 years, n (%) 132 (17.1) 8 (14.8) 124 (17.3)
>50–60 years, n (%) 205 (26.5) 17 (31.5) 188 (26.2)
>60 years, n (%) 291 (37.8) 13 (24.1) 278 (38.8)
Race, n (%) 0.46
White 596 (90.3) 45 (83.3) 651 (90.8)
Hispanic 18 (2.3) 2 (3.7) 16 (2.2)
Black 31 (4.0) 4 (7.4) 27 (3.8)
Asian 12 (1.2) 1 (1.9) 11 (1.5)
American Indian/Pacific Islander 14 (1.8) 2 (3.7) 12 (1.7)
Donor type, n (%) 0.13
Deceased donor 134 (17.4) 7 (13.0) 127 (17.7)
Living related donor 295 (38.3) 16 (29.6) 279 (38.9)
Living unrelated donor 342 (44.4) 31 (57.4) 311 (43.4)
Sex (male), n (%) 483 (62.6) 30 (55.6) 453 (63.2) 0.31
Cause of ESRD, n (%) 0.73
Diabetes 143 (18.5) 7 (13.0) 136 (19.0)
Glomerulonephritis 275 (35.7) 19 (35.2) 255 (35.6)
Hypertension 45 (5.8) 5 (9.3) 40 (5.6)
Cystic renal diseases 130 (16.9) 9 (16.7) 121 (16.9)
Other 130 (16.9) 11 (20.4) 119 (16.6)
Unknown 48 (6.2) 3 (5.7) 45 (6.3)
cPRA, %, mean  SD 12.3  27.1 8.9  22.7 12.6  27.3 0.27
Prior solid organ transplant, n (%) 131 (17.0) 13 (24.07) 108 (16.5) 0.19
Induction, n (%) 0.06
Thymoglobulin 388 (50.3) 27 (50.0) 361 (50.4)
Basiliximab 235 (30.5) 10 (18.5) 224 (31.3)
Alemtuzumab 147 (19.1) 17 (31.5) 130 (18.2)
HLA mismatch (>1), n (%) <0.01
A 573 (74.9) 50 (93.0) 523 (72.9)
B 530 (82.4) 49 (92.6) 581 (81.0)
DR 584 (76.4) 49 (90.7) 535 (74.6)
DQ 535 (69.5) 49 (90.7) 486 (67.8)
HLA mismatch, mean  SD 3.3  1.9 4.2  1.5 3.6  1.9 <0.01
Polyomavirus, n (%)1 34 (4.4) 5 (9.3) 29 (4.0) 0.08
Acute cellular rejection,1 n (%) 132 (17.1) 19 (35.2) 113 (15.8) <0.01
Documented medication nonadherence, n (%) 53 (8.2) 18 (33.3) 45 (6.3) <0.01
Follow-up (years), mean  SD 4.2  1.9 4.7  2.0 4.2  1.9 0.06
Follow-up after dnDSA detection (years), mean  SD NA 3.2  2.0 NA NA
cPRA, calculated panel reactive antibody; dnDSA, de novo donor-specific antibody; ESRD, end-stage renal disease; NA, not assessed;
SD, standard deviation.
1Present prior to dnDSA detection.
American Journal of Transplantation 2017; 17: 1574–1584 1577
Protocol Biopsies and dnDSA
At the time of dnDSA detection, 20.0% (8 of 40) of the
biopsies met Banff criteria for acute cellular rejection
(borderline grade or higher); 25.0% (10 of 40) of the
biopsies met criteria for acute, active AMR; and 7.5% (3
of 40) of the biopsies showed chronic AMR (with con-
comitant acute, active AMR) (Figure 4). The prevalence
of acute, active AMR and chronic AMR increased to
52.9% (18 of 34) and 38.2% (13 of 34), respectively, by
1 year following dnDSA detection (p = 0.04 and
p = 0.02, respectively), whereas the prevalence of acute
cellular rejection was unchanged (20.0% [8 of 40] vs.
14.7% [5 of 34], p = 0.76) (Figure 4).
Overall, 65.2% (30 of 46) of the surviving allografts had
biopsies ≥2 years after dnDSA detection. Acute, active
AMR was present in 33.3% (10 of 30) and chronic AMR
was present in 16.7% (5 of 30) of those remaining allo-
grafts. Only three patients (10% of patients who
received a biopsy >1 year after dnDSA detection) had
newly detected acute, active AMR that was not present
at baseline or 1 year after dnDSA detection.
The individual Banff scores at the time of and at 1 year after
dnDSA detection are presented in Figure 5. The prevalence
of moderate glomerulitis numerically increased in the year
following dnDSA detection, but this did not reach statistical
significance (12.5% [5 of 40] up to 32.3% [11 of 34],
Table 2: Risk factors for de novo donor-specific antibody
Risk factor
Univariate Multivariate model 1 Multivariate model 2
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value
Age (years)
18–30 2.0 (0.9–4.5) 0.12 – – – –
>30–40 1.6 (0.7–3.5) 0.24 – – – –
>40–50 0.8 (0.4–1.8) 0.85 – – – –
>50–60 1.3 (0.7–2.3) 0.43 – – – –
>60 0.5 (0.3–1.0) 0.04 0.7 (0.3–1.4) 0.31 – –
Induction
Thymoglobulin 1.0 (0.6–1.7) 1.0 – – – –
Basiliximab 0.5 (0.2–1.0) 0.05 – – – –
Alemtuzumab 2.1 (1.1–3.8) 0.03 1.5 (0.7–2.9) 0.26 – –
HLA mismatch (>1)
A 4.5 (1.6–12.5) <0.01 2.5 (0.82–9.5) 0.14 – –
B 2.2 (0.9–5.6) 0.10 – – – –
DR 3.2 (1.3–8.1) <0.01 1.5 (0.5–5.2) 0.48 4.8 (2.0–14.3) <0.01
DQ 4.6 (1.8–11.7) <0.01 3.5 (1.4–10.7) 0.01 – –
HLA mismatch NA – 1.1 (1.3–0.9)
per mismatch
0.42 – –
Acute cellular rejection1 2.9 (1.6–5.2) <0.01 2.6 (1.3–5.1) ≤0.01 2.4 (1.3–4.5) <0.01
Documented medication
nonadherence
7.5 (3.9–14.2) <0.01 6.4 (3.1–13.3) <0.01 7.9 (3.9–15.4) <0.01
CI, confidence interval; OR, odds ratio.
1Prior to de novo donor-specific antibody formation.
Table 3: De novo donor-specific antibody characteristics
Class I (alone) Class II (alone) Classes I and II Class I (total) Class II (total)
% (n) 9.3% (5) 70.4% (38) 20.4% (11) 29.6% (16) 90.7% (49)
Mean  SD 1668.21  1411.5 3612.01  3425.1 4348.21  5040.6 2075.81  2211.1 3949.51  4903.6
Median (IQR) 1492 (1000–2708.5) 1923 (1274.5–4749.5) 2800.5 (1435–4881.5) 1462 (1083.75–2552) 2176 (1103–4117)
IQR, interquartile range; SD, standard deviation.
Figure 2: Time to dnDSA detection. The mean time to dnDSA
detection after transplant was 1.8  1.6 years. At our center,
surveillance testing for dnDSA is performed at 4 mo after trans-
plant and yearly thereafter. Testing for dnDSA is also obtained
for clinical indication (i.e. acute cellular rejection). dnDSA, de
novo donor-specific antibody.
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p = 0.07). The prevalence of peritubular capillaritis, tubulitis,
acute interstitial inflammation, endothelialitis, chronic vas-
cular lesions, interstitial fibrosis, tubular atrophy, arteriolar
hyalinosis, and C4d positivity was unchanged in the year fol-
lowing dnDSA detection, whereas the prevalence of
chronic AMR (Banff cg >0) increased (7.5% [3 of 40] up to
38.2% [13 of 34], p = 0.02) (Figure 5).
Allograft function
At the time of dnDSA detection, the mean iothalamate
clearance was 55.0  20.4 mL/min per body surface area
(BSA), and at 1 year after detection, it decreased to
52.5  18.6 mL/min per BSA (p < 0.01, paired t-test) (Fig-
ure 6). At the end of follow-up (a mean of 3.2  2.0 years
following dnDSA detection), the mean iothalamate GFR
Figure 3: Patient and allograft survival. Patients with dnDSA had reduced death-censored allograft survival (p = 0.01). At the end
of follow-up, actuarial death-censored allograft survival was 87.0% in patients who developed dnDSA and 97.0% in patients who did
not develop dnDSA (p = 0.01). Cox regression with a time-dependent variable (dnDSA) was used to compare groups (Wald test at the
0.05 level). dnDSA, de novo donor-specific antibody.
Figure 4: Allograft rejection at dnDSA detection and at 1 year. The prevalence of acute cellular rejection remained similar at
1 year after dnDSA detection, but there was increased acute, active AMR and chronic AMR. The definition of acute, active AMR was
Banff scores (i) ptc + g >2 or (ii) ptc >0 or g >0 and C4d >1. Chronic AMR was present if the Banff transplant glomerulopathy score
was cg >0. All patients with chronic AMR had concomitant acute, active AMR. McNemar paired analysis was used to compare serial
biopsies. AMR, antibody-mediated rejection; dnDSA, de novo donor-specific antibody.
American Journal of Transplantation 2017; 17: 1574–1584 1579
Protocol Biopsies and dnDSA
decreased to 44.5  21.7 mL/min per BSA (p = 0.01,
paired t-test). The 24-h urine proteinuria increased from
391.4  865.5mg to 603.6  1035.8 mg, but this did not
reach statistical significance (p = 0.24, paired t-test).
Which patients with dnDSA developed allograft
failure or reduced eGFR?
Patients with dnDSA were followed 3.2  2.0 years after
dnDSA detection, and their outcomes were compared
with those of patients without dnDSA. Patients with
dnDSA had increased incidence of allograft failure
(13.0% [7 of 54] vs. 2.9% [21 of 717], p < 0.01); the
composite end point of graft failure and/or 50% reduction
in eGFR (27.8% [15 of 54] vs. 9.6% [69 of 717],
p < 0.01); acute, active AMR (54.9% [28 of 51] vs. 8.1%
[57 of 702], p < 0.01); and chronic AMR (37.2% [19 of
51] vs. 6.8% [48 of 703], p < 0.01) compared with those
patients without dnDSA (Figure 7).
The incidence of graft failure and the composite end
point was similar among patients with only class I, only
class II, and no dnDSA detected during follow-up
Figure 5: Allograft histology at dnDSA detection and at 1 year. The prevalence of chronic AMR increased in the year following
the detection of dnDSA. McNemar paired analysis was used to compare serial biopsies. AMR, antibody-mediated rejection; dnDSA,
de novo donor-specific antibody.
Figure 6: Allograft function and proteinuria when dnDSA detected and at follow-up. At the time of dnDSA detection, the mean iothala-
mate clearance was 55.0  20.4 mL/min per BSA, and at 1 year after detection, it decreased to 52.5  18.6 mL/min per BSA (p < 0.01,
paired t-test). During the entire follow-up following dnDSA detection (mean 3.2  2.0 years), mean iothalamate GFR decreased to
44.5  21.7 mL/min per BSA (p = 0.01). During the same follow-up, mean 24-h urine proteinuria increased from 391.4  865.5 mg to
603.6  1035.8 mg, but this did not reach statistical significance (p = 0.24). BSA, body surface area; dnDSA, de novo donor-specific antibody.
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(Figure 7). In contrast, incidence of both end points was
higher in patients with both class I and II dnDSA
detected. Graft failure and the composite end point
occurred in 54.6% (6 of 11) of patients with both class I
and II dnDSA (p < 0.01 compared with no dnDSA)
(Figure 7).
In contrast, the incidence of acute, active AMR and
chronic AMR was higher in patients with dnDSA regard-
less of the class of dnDSA present (Figure 7). The inci-
dence of acute, active AMR was 60.0% (3 of 5), 52.8%
(19 of 36), and 70.0% (7 of 10) in patients with class I,
class I, and classes I and II dnDSA, respectively
(p < 0.01 for all classes). Chronic AMR was detected in
60.0% (3 of 5), 30.6% (11 of 36), and 50.0% (5 of 10)
of patients with only class I, only class II, and both
class I and II dnDSA, respectively (p < 0.01 for all
classes).
No patients lost their allograft during follow-up if their
dnDSA completely disappeared. The rates of the com-
posite end point; acute, active AMR; and chronic AMR
were similar in patients with transient dnDSA compared
with patients without dnDSA (Figure 8).
There were numeric trends toward increased allograft fail-
ure and the composite end point in patients with a higher
total sum MFI at baseline, but this did not reach statistical
significance (p = 0.09 and p = 0.44, respectively; Cochran
test for trend). Patients with a total MFI 3000–6000 and
>6000 had higher rates of acute, active AMR compared
with patients with total MFI >3000 at baseline (p = 0.03,
Cochran test for trend). Specifically the rate of acute,
active AMR was 39.3% (11 of 28) in patients with MFI
<3000 at baseline, 75.0% (8 of 11) in patients with
MFI 3000–6000 at baseline, and 72.7% (8 of 11) with MFI
>6000 at baseline. The rate of chronic AMR was similar in
patients regardless of baseline total dnDSA MFI (Figure 8).
Of all patients with dnDSA, only those with histologic evi-
dence of acute, active AMR either at DSA detection or on
subsequent biopsy had an increased incidence of graft fail-
ure and/or 50% reduction in eGFR (Figure 9). Overall,
21.4% (6 of 28) of the allografts failed in patients with
Figure 7: Allograft failure, eGFR decline, and AMR in patients with and without dnDSA. Graft failure; the composite end point
of graft failure and/or 50% reduction in GFR; acute, active AMR; and chronic AMR were higher in patients with dnDSA. Patients with
both classes I and II dnDSA had the highest rate of graft loss and 50% decline in eGFR. Overall, 94.4% (51 of 54) of patients received
a biopsy. The mean follow-up after dnDSA detection was 3.2  2.0 years. *No patients with class I dnDSA only lost their allografts
during follow-up. †All statistical comparisons were with the no dnDSA group. AMR, antibody-mediated rejection; dnDSA, de novo
donor-specific antibody; eGFR, estimated GFR.
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dnDSA and AMR, whereas none failed in patients with
dnDSA and no AMR (p < 0.01 for dnDSA plus AMR vs. no
dnDSA; p = 1.0 for dnDSA without AMR vs. no dnDSA).
The incidence of graft failure and/or 50% reduction in
eGFR occurred in 35.7% (10 of 28) of patients with dnDSA
and AMR, 17.3% (4 of 23) of those with dnDSA and no
AMR, and 9.6% (69 of 717) of patients with no dnDSA
(p < 0.01 for dnDSA plus AMR vs. no dnDSA; p = 0.26 for
dnDSA without AMR vs. no dnDSA).
Discussion
The presence of dnDSA is associated with AMR and allo-
graft loss, but most patients actually have a functioning
allograft for the first few years after dnDSA detection. In
this study, patients with both anti–class I and II dnDSA
had the highest rate of graft loss and the composite end
point of graft loss and/or 50% reduction in eGFR. More
than half of this small subgroup of patients had allograft
failure within 3.2 years following dnDSA detection. We
also found that, regardless of the class of dnDSA pre-
sent, only those patients who developed AMR (i.e.
microvascular inflammation) had allograft failure or the
composite end point of allograft failure or 50% eGFR,
even when the vast majority of the AMR episodes in our
cohort were subclinical. No patients in the dnDSA group
without AMR had allograft loss.
The use of protocol biopsy allowed us to better under-
stand the progression to AMR after dnDSA. When
dnDSA was detected, only 25.0% had histologic findings
of acute, active AMR, but the incidence increased to
52.9% by 1 year after dnDSA detection. Consequently,
patients without histologic evidence of AMR at the time
of dnDSA detection may benefit from a follow-up biopsy
within 1 year after dnDSA detection because AMR may
be missed on the initial biopsy. Finding new AMR on
biopsies performed >1 year after dnDSA detection was
unusual, which suggests that some patients with dnDSA
never develop AMR. This deserves further study.
Although the SAB output is semiquantitative, the sum MFI
of dnDSA at baseline has some prognostic value: The
higher the sum MFI at baseline, the higher the incidence
of acute, active AMR. In addition, patients whose dnDSA
completely disappeared during follow-up had similar rates
of graft failure; the composite end point of graft failure and
Figure 8: Allograft function and histology stratified by dnDSA MFI. The rates of allograft loss; the composite end point; acute,
active AMR; and chronic AMR were similar in patients with transient dnDSA compared with patients without dnDSA. A higher sum
MFI of dnDSA at baseline was associated with higher rates of acute, active AMR (p = 0.03, Cochran test for trend). *Comparison
between outcomes in patients with no dnDSA and with transient dnDSA. †Cochran test for trend comparison outcomes in patients
with dnDSA MFI <3000, 3000–6000, and >6000 at baseline. AMR, antibody-mediated rejection; dnDSA, de novo donor-specific anti-
body; eGFR, estimated GFR; MFI, mean fluorescence intensity.
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50% decline in eGFR; acute, active, AMR; and chronic
AMR as those without dnDSA. Moreover, dnDSA com-
pletely disappeared in only a small number of patients—a
phenomenon that also deserves further study.
Other studies on this subject have also reported detailed
histologic findings following dnDSA, but most biopsies
were obtained at the time of dnDSA detection (2) or for
allograft dysfunction (3,9). The incidence of AMR at the
time of dnDSA detection was lower than that reported in
other cohorts (6,9), but that was likely because biopsies
performed in our cohort were mainly performed for surveil-
lance and not for allograft dysfunction. Our results are par-
ticularly informative because we studied biopsies at more
than one time point (mean of three biopsies per patient).
We also confirmed many previously reported findings. Like
de Kort et al, we found that the presence of microvascular
inflammation (acute, active AMR in our cohort) was associ-
ated with allograft failure (9). The overall incidence of
dnDSA in our cohort was also consistent with that previ-
ously reported (2,3,6,13), and we found that DQ mismatch,
prior medication nonadherence, and acute cellular rejection
were linked to the development of dnDSA (2,3,6).
The main limitation of our study was the relatively short
follow-up. We reported the most comprehensive histologic
follow-up after dnDSA, but the same patients did not
have biopsies at all time points, which limited our ability
to truly describe the evolution and timing of light micro-
scopic findings. We also did not assess the impact of
epitope mismatches on dnDSA development (14) or the
effect of DSA characteristics such as titer, IgG sub-
classes, or C1q (15,16) on prognosis. Finally, we used a
50% reduction in eGFR as a clinical outcome, although it
is not currently approved by the U.S. Food and Drug
Administration for clinical trials in transplantation (17–19).
These data reemphasize the importance of developing
effective therapy either to prevent dnDSA formation or
to treat its consequences; however, designing a clinical
trial to study this is difficult. We believe a prevention trial
is unreasonable, given the relatively low incidence of
dnDSA. As others have already discussed (6), a multicen-
ter effort with thousands of patients would be required
to adequately power a study, and many patients would
be treated unnecessarily. Even a treatment trial in
patients with identified dnDSA would require a prolonged
multicenter effort. The best approach may be to enroll
dnDSA patients with acute, active AMR into a treatment
trial because this is a large subset of patients at the
greatest risk of graft failure. This approach would mini-
mize the number of patients treated unnecessarily and
Figure 9: Acute, active AMR and dnDSA associated with allograft failure and eGFR decline. *No dnDSA patients without AMR
lost their allograft during follow-up. †All statistical comparisons were to the no dnDSA group. AMR, antibody-mediated rejection;
dnDSA, de novo donor-specific antibody; eGFR, estimated GFR.
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maximize the potential to detect a meaningful effect
from a potential therapeutic agent.
In conclusion, the development of dnDSA is associated
with a progressive increase in antibody-mediated injury in
more than half of patients within 1 year of detection.
The patients who ultimately developed AMR were at
high risk of graft failure and/or 50% reduction in GFR.
Nevertheless, there are potentially modifiable risk factors
including ensuring medication adherence and avoiding
HLA mismatch, especially at the DQ locus.
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